• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    11/3/23 9:05:47 AM ET
    $ABCL
    $AGL
    $ARQT
    $CVRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $ABCL alert in real time by email

    Gainers

    • Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $54.5 million.
    • Werewolf Therapeutics (NASDAQ:HOWL) shares rose 20.0% to $2.58. The company's market cap stands at $91.9 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) stock rose 16.93% to $0.37. The market value of their outstanding shares is at $7.7 million.
    • Altamira Therapeutics (NASDAQ:CYTO) shares moved upwards by 14.98% to $0.19. The company's market cap stands at $1.4 million.
    • Arcutis Biotherapeutics (NASDAQ:ARQT) shares moved upwards by 13.96% to $2.53. The market value of their outstanding shares is at $238.2 million. As per the press release, Q3 earnings came out today.
    • CVRx (NASDAQ:CVRX) stock moved upwards by 13.8% to $15.5. The market value of their outstanding shares is at $322.6 million.

    Losers

    • Panbela Therapeutics (NASDAQ:PBLA) stock fell 30.5% to $0.66 during Friday's pre-market session. The market value of their outstanding shares is at $1.9 million.
    • NexImmune (NASDAQ:NEXI) shares decreased by 28.75% to $2.65. The market value of their outstanding shares is at $2.8 million.
    • Agilon Health (NYSE:AGL) shares fell 14.04% to $14.52. The company's market cap stands at $5.8 billion. As per the news, the Q3 earnings report came out yesterday.
    • Erasca (NASDAQ:ERAS) shares declined by 12.06% to $2.07. The company's market cap stands at $312.1 million.
    • Turnstone Biologics (NASDAQ:TSBX) shares decreased by 11.86% to $2.9. The company's market cap stands at $66.2 million.
    • AbCellera Biologics (NASDAQ:ABCL) shares declined by 10.16% to $3.98. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q3 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABCL
    $AGL
    $ARQT
    $CVRX

    CompanyDatePrice TargetRatingAnalyst
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    Erasca Inc.
    $ERAS
    1/7/2026$5.00Overweight
    Piper Sandler
    Werewolf Therapeutics Inc.
    $HOWL
    12/19/2025$1.00Outperform → Neutral
    Wedbush
    AbCellera Biologics Inc.
    $ABCL
    11/7/2025$4.00Outperform → Market Perform
    Leerink Partners
    Erasca Inc.
    $ERAS
    10/16/2025$4.00Buy
    Stifel
    Erasca Inc.
    $ERAS
    9/3/2025Buy → Underperform
    BofA Securities
    agilon health inc.
    $AGL
    8/20/2025$1.40Outperform → Mkt Perform
    Bernstein
    Erasca Inc.
    $ERAS
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ABCL
    $AGL
    $ARQT
    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Erasca with a new price target

    Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

    1/7/26 9:10:17 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics downgraded by Wedbush with a new price target

    Wedbush downgraded Werewolf Therapeutics from Outperform to Neutral and set a new price target of $1.00

    12/19/25 9:28:37 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Wulf John William bought $50,941 worth of shares (81,000 units at $0.63), increasing direct ownership by 28% to 365,857 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    1/30/26 7:30:58 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

    WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler & Co. ("Piper Sandler") to serve as exclusive financial advisor to assist in the strategic evaluation process. "We have initiated a process to explore a ran

    2/24/26 4:09:32 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Reports Full Year 2025 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of p

    2/24/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    SEC Filings

    View All

    SEC Form S-8 filed by Arcutis Biotherapeutics Inc.

    S-8 - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)

    2/25/26 4:19:27 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Arcutis Biotherapeutics Inc.

    S-3ASR - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)

    2/25/26 4:16:34 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by agilon health inc.

    10-K - agilon health, inc. (0001831097) (Filer)

    2/25/26 4:12:09 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Officer Matsuda Masaru sold $1,027,293 worth of shares (40,638 units at $25.28), decreasing direct ownership by 27% to 110,003 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    2/4/26 8:35:55 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    Leadership Updates

    Live Leadership Updates

    View All

    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

    WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as a consultant for the Company. "As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board," said Frank Watanabe, president and chi

    12/8/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Appoints Dr. Stephen Quake to its Board of Directors

    AbCellera (NASDAQ:ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. "We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology," said Carl Hansen, Ph.D., fo

    11/10/25 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    Financials

    Live finance-specific insights

    View All

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Reports Full Year 2025 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of p

    2/24/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarterTotal revenue for 2025 was $56.7 million, an increase of 10% over the prior yearActive implanting centers

    2/12/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $ABCL
    $AGL
    $ARQT
    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

    SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

    11/14/24 4:11:49 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care